MeSH D020256 - choroidal neovascularization
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D009389:Pathologic neovascularization
0 Companies
0 Drugs
Success rate
D015862:Choroid diseases
0 Companies
0 Drugs
Success rate
D020256:
Choroidal neovascularization
D000092342:Polypoidal choroidal vasculopathy
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Bausch Health Companies | Verteporfin | Visudyne | 2000-04-12 | |||
| CHEPLAPHARM Arzneimittel | Verteporfin | Visudyne | 2000-07-27 | |||
| Novartis | Ranibizumab | Lucentis | 2007-01-22 | $1,848 M | Q2/20-Q2/23 |
Clinical Trials
Historical Success Rate
Phase 1
86%12/14
Phase 2
41%7/17
Phase 3
36%4/11
Approved: 1Overall Success rate: 13%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use